Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 16

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 16
---
therapeutic treatments. DiamiR has devoted most of its financial resources to conducting studies on quantitative analysis of circulating
organ-enriched microRNAs as biomarkers of brain health and other disorders, building its patent portfolio, and maintaining DiamiR laboratory
status as CLIA and CAP certified laboratory. DiamiR has not completed development of any product candidate and has therefore not generated
any revenues from product sales, and currently its only source of revenue is from investments made from time to time by its officers and
directors and from a Small Business Innovation Research (SBIR) grant in the original amount of $3,359,115 that it received in 2020, which
is insufficient to carry out its business plans. DiamiR has incurred net losses in each year since inception, including net losses of
$614,405 and $1,318,431 for the years ended May 31, 2024 and 2023, respectively, and $493,710 for the nine months ended February 28, 2025.
At February 28, 2025, DiamiR had an accumulated deficit of $5,573,046 primarily due to operating expenses. Because of the numerous risks
and uncertainties associated with the development of its LDTs, DiamiR is unable to accurately predict the timing or amount of increased
expenses or when, or if, it will be able to achieve or maintain profitability; DiamiR also expects to incur increased expenses as it conducts
clinical studies. DiamiR also expects an increase in expenses associated with creating additional infrastructure (including hiring additional
personnel) to complete the development and launch of CogniMIR, a proprietary test for early detection and risk stratification
of MCI and AD.

From June 2020 through April 2023, Kira Sheinerman, one of the founders
and the Executive Director of DiamiR, served as senior strategic consultant to Aptorum, which role included reviewing therapeutic and
diagnostic opportunities, and making industry and academia introductions for Aptorum. Kira Sheinerman currently hold 2,772 shares of Aptorum.

Company management believes
that by merging these two companies together, it can achieve greater shareholder value and have a stronger growth trajectory.

<div align='center'>3</div>

Merger Agreement with DiamiR

Pursuant to the Letter of Intent, we entered into the Merger Agreement
with DiamiR on July 14, 2025 for the D